Home Metabolism -Proteases PCSK9

PCSK9

PCSK9 Products

  • All (13)
  • PCSK9 Inhibitors (4)
  • PCSK9 Antibodies (8)
  • PCSK9 Antagonist (1)
  • New PCSK9 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Med (Lausanne), 2024, 11:1284199
PeerJ, 2024, 12:e17676
A2843 Ebronucimab (Anti-PCSK9) Ebronucimab (Anti-PCSK9) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used to treat hyperlipidemia. MW : 144.76 KD.
A2047 Alirocumab (anti-PCSK9) Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
A2876 Frovocimab (Anti-PCSK9) Frovocimab (Anti-PCSK9) is a humanized IgG4 monoclonal antibody that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). MW: 146.88 KD.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
A2924 Lodelcizumab (Anti-PCSK9) Lodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
A2987 Ongericimab (Anti-PCSK9) Ongericimab (Anti-PCSK9) is a humanized monoclonal antibody targeting PCSK9. It has lipid-lowering efficacy and can be used in research of hypercholesteremia and hyperlipidemia. MW :143.04 KD.
A2043 Evolocumab (anti-PCSK9) Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
Front Med (Lausanne), 2024, 11:1408760
A2788 Bococizumab (Anti-PCSK9) Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD.
A2789 Anti-PCSK9 (Boehringer anti-PCSK9) Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
A2843 Ebronucimab (Anti-PCSK9) Ebronucimab (Anti-PCSK9) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used to treat hyperlipidemia. MW : 144.76 KD.
A2047 Alirocumab (anti-PCSK9) Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
A2876 Frovocimab (Anti-PCSK9) Frovocimab (Anti-PCSK9) is a humanized IgG4 monoclonal antibody that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). MW: 146.88 KD.
A2924 Lodelcizumab (Anti-PCSK9) Lodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD.
A2987 Ongericimab (Anti-PCSK9) Ongericimab (Anti-PCSK9) is a humanized monoclonal antibody targeting PCSK9. It has lipid-lowering efficacy and can be used in research of hypercholesteremia and hyperlipidemia. MW :143.04 KD.
A2043 Evolocumab (anti-PCSK9) Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
Front Med (Lausanne), 2024, 11:1408760
A2788 Bococizumab (Anti-PCSK9) Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD.
A2789 Anti-PCSK9 (Boehringer anti-PCSK9) Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD.
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Med (Lausanne), 2024, 11:1284199
PeerJ, 2024, 12:e17676

Choose Selective PCSK9 Inhibitors

Tags: PCSK9 inhibitor|PCSK9 agonist|PCSK9 activator|PCSK9 inducer|PCSK9 antagonist|PCSK9 signaling pathway|PCSK9 assay kit